# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0001193125-26-029517
**Filing Date:** 2026-1
**Character Count:** 2720
**Document Hash:** a78b5fb2f1ee379570a0d39febb5099c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-029517.hdr.sgml**: 20260422

**ACCESSION NUMBER**: 0001193125-26-029517

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260129

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121

![LOGO](g53438g0130021842104.jpg)

January 29, 2026

**<u>VIA EDGAR AND EMAIL</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attn: Tim Buchmiller

---

| | |
|:---|:---|
| **Re:** | **Dianthus Therapeutics, Inc.**  |

---

**Registration Statement on Form S-3** 

**Filed January 28, 2026** 

**File No. 333-293014** 

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Dianthus Therapeutics, Inc., a Delaware corporation (the "Company"), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:00 p.m., Eastern Standard Time, on January 30, 2026 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Melanie Neary at (415) 393-8243.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **Dianthus Therapeutics, Inc.** | **Dianthus Therapeutics, Inc.** |
| By: | /s/ Ryan Savitz |
| Name: | Ryan Savitz |
| Title: | Chief Financial Officer and Chief Business Officer |

---

cc: Marino Garcia, Dianthus Therapeutics, Inc. Adam Veness, Dianthus Therapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP